Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. Ophthalmology Spin-Out Raises £8m For DME Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

SV Life Sciences and Novo AS support spin-out KalVista with £8m to advance preclinical DME programs.
Advertisement

Related Content

KalVista’s Novel DME Approach Moves To Clinical Trials
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Shrinking Funding Rounds For European Biotechs Are No Surprise, But Series A Rounds Look Healthy, If Few
ThromboGenics Delays Diabetic Retinopathy Study; On Track To File Ocriplasmin For Retinal Adhesions
U.K. Newco Raises £6 Mil. To Discover Ubiquitin-Targeting Cancer Drugs
Vantia Tops Up With £4 mill Series B To Pursue Nocturia And Dysmenorrhea
Vantia Tops Up With £4 mill Series B To Pursue Nocturia And Dysmenorrhea
Financings Of The Fortnight: Shield Therapeutics Reveals Switzerland As Series A Hot Spot
FDA Issues "Complete Response" On Alimera's Iluvien; Eyes More Data
Sanofi Creates Ophtho Division through Earn-Out Acquisition of Fovea

Topics

Advertisement
UsernamePublicRestriction

Register

PS072676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel